News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company's ties to the UK. Britain's second-most valuable company has held talks with Bristol Myers Squibb in recent months about a …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …
AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …
Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca announced that the European Commission has approved its antibody-drug conjugate, Datroway, developed with Daiichi Sankyo, for a second breast cancer indication in the EU. This approval means the intravenous infusion will be available in the 27 EU member states, expanding its use for …
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) has received approval in the EU as a monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. This approval is based on …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AstraZeneca reported positive Phase III results for sonesitatug vedotin in Claudin 18.2-positive advanced gastric …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca stock has delivered a 73.3% total return over the past five years, and both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca PLC (AZN) had approximately 97,021 employees worldwide as of March 2026, representing a 13.5% growth from 2023 but a 0.7% decline year-over-year in 2026. The company is actively hiring, with 3,640 job postings in 2026, and its workforce is primarily concentrated in the …
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company focused on oncology and other major therapeutic areas, could gain a potential new cancer treatment with estimated peak sales between $3 billion and $5 billion after a late-stage study produced positive topline …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%A federal court has dismissed AstraZeneca's attempt to block a Maine law that regulates drug companies' contracts with pharmacies. The US District Court for the District of Maine granted the state's motion to dismiss, upholding Chapter 103 of its insurance code. This law prohibits …
AstraZeneca's drug pipeine is splitting opinion among City analysts Proactive uses images sourced from Shutterstock AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank repeated a 'sell' rating …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company focused on medicines including cancer and rare-disease treatments, maintained its 2026 and 2030 forecasts after second-quarter core earnings exceeded market expectations, helping ease some investor concern following recent clinical-trial setbacks. Core earnings …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%This article provides key financial results for AstraZeneca PLC's second quarter, highlighting revenues of $15.38 billion. The exact details of the earnings, including comparisons to estimates or prior periods, would be expected in the full content.
This article first appeared on GuruFocus. Total Revenue Growth: 6% increase in the first half of 2026. Product Revenue Growth: 6% increase in the first half of 2026. Alliance Revenue Growth: 29% increase, driven by higher profit shares from partnered medicines. Core Gross Margin: …
Sharemaestro market context Price below Trend Line 52 weeks -4.0%AstraZeneca AZN reported second-quarter 2026 core earnings of $2.63 per share, which beat the Zacks Consensus Estimate of $2.50. Earnings rose 21% year over year on a reported basis and 18% at constant exchange rate (CER). Total revenues of $15.38 billion rose 6% on …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca has announced an update on its MONTEROSA study, which tracks the real-world use of its STRIDE regimen (tremelimumab and durvalumab) for liver cancer across Italian centers. The observational study aims to assess patient progression to serious liver problems, quality of life, and the …
[blood cells] cosmin4000/iStock via Getty Images * The failure of a phase 3 trial of AstraZeneca's (AZN [https://seekingalpha.com/symbol/AZN]) Ultomiris (ravulizumab) phase to treat transplant-associated thrombotic microangiopathy, a rare disorder leading to blood clots and harm to small blood vessels, has led shares of Omeros …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%The Dow Jones Industrial Average was up, while the S&P 500 and Nasdaq Composite were down in late-mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca is adjusting its pricing strategy for new drug launches in response to former U.S. President Donald Trump's "most-favoured-nation" policy, which aims to lower drug prices for Americans. This policy links U.S. medicine prices to those in other wealthy countries, intensifying pressure on European …
Astrazeneca (AZN) reported $15.38 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 6.4%. EPS of $2.63 for the same period compares to $2.18 a year ago. The reported revenue represents a surprise of +0.48% over the Zacks Consensus …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Key Points Interested in Astrazeneca Plc? Here are five stocks we like better. Solid first-half performance: AstraZeneca reported revenue growth of 6% at constant exchange rates and 11% excluding generic-competition effects, while core EPS rose 11%. The company maintained its full-year outlook and reaffirmed …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca reported solid Q2 2026 core EPS growth, but faces significant risks due to the patent expiry of its key treatment, Farxiga, in the U.S. and its inclusion in China's procurement program. While the company's weight loss drug candidate offers some positive offsets, the …
AstraZeneca reported second-quarter results on Monday that topped profit expectations, with the Anglo-Swedish pharmaceutical company holding its 2026 guidance and $80 billion annual revenue target for 2030. Core earnings per share reached $2.63 for the three months ended June 30, a gain of 18% …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Earnings season kicks into high gear this week. AstraZeneca (AZN) and Nucor (NUE) report on Monday, with results from SK Hynix (SKHY), Visa (V), Coca-Cola (KO), Boeing (BA), Ford (F), ExxonMobil (XOM), and Chevron (CVX) coming later in the week. The main focus, though, …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Earnings season kicks into high gear this week. AstraZeneca (AZN) and Nucor (NUE) report on Monday, with results from SK Hynix (SKHY), Visa (V), Coca-Cola (KO), Boeing (BA), Ford (F), ExxonMobil (XOM), and Chevron (CVX) coming later in the week. The main focus, though, …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca reconfirmed its outlook for the full year (Hector RETAMAL) British pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs. Profit after tax climbed more than two percent …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01 is the first Phase III trial to show overall survival benefit with an anti-CLDN18.2 ADC in this setting First pivotal readout from AstraZeneca's wholly owned …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 CAMBRIDGE, England, July 27, 2026--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2026 % Change Q2 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 28,896 …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca has revealed that demand for its range of cancer treatments buoyed sales this year as the drugs giant increased spending on new research. The Cambridge-based company said sales growth within its oncology and rare disease divisions helped deliver a boost. It reported total …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%(RTTNews) - British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share grew from last year with higher revenues, excluding weak China results. Further, the firm confirmed fiscal 2026 outlook for …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Search by ticker symbol or company name and select a result to open its chart.